Huapont Invests $6 Million In San Diego's Histogen, Inc.

Huapont Life Sciences of Chongqing made a $6 million investment in Histogen, a San Diego company that is developing a stem cell treatment for hair loss. Huapont's investment will anchor Histogen's planned $18 million Series D funding. In return, Huapont will help Histogen develop its Hair Stimulating Complex (HSC), an injectable product based on cultured skin cells, in China. So far, HSC has shown efficacy in two US clinical trials.